The Legal Examiner Affiliate Network The Legal Examiner The Legal Examiner The Legal Examiner search feed instagram google-plus avvo phone envelope checkmark mail-reply spinner error close The Legal Examiner The Legal Examiner The Legal Examiner
Skip to main content

The popular diabetes drug Actos® (pioglitazone), which is marketed as Actos, Actoplus Met, and Duetact, has been linked with an increased risk of bladder cancer. Actos is manufactured and sold by Takeda Pharmaceuticals.

People who have taken Actos and suffered from bladder cancer or experience bladder cancer symptoms (blood in urine with or without pain, painful sides/flanks, distended bladder, etc.), should contact a doctor immediately. You might also have a legal claim.

The Spangenberg Law Firm is pursuing investigations for people who have taken a diabetes drug like Actos and suffered from bladder cancer. Currently, there are at least a dozen Actos lawsuits pending. This is not a situation in which you should delay, either. Each state has a “statute of limitations” period in which you must file a lawsuit, or you will not be allowed to pursue your claim.

Because the Actos manufacturer may have failed to adequately warn of these risks, or design a safe product, you may be entitled to compensation if you have been diagnosed with bladder cancer or a cancerous bladder tumor.

An experienced Actos lawyer like those at the Spangenberg Law Firm (toll free: 1-877-696-3303) can help you determine whether you have a case, the statute of limitations time left, and answer any question you might have about the process. Because we work on a contingency fee basis, there is no cost to you to pursue a claim. Rather, our payment and the case expenses only come out of a recovery, and there is never an out-of-pocket cost to you.

To have a potential bladder cancer lawsuit reviewed by one of our Actos lawyers, request a free consultation and claim evaluation by going to http://actos-bladder-cancer-lawyers.com or calling us toll free at 1-877-696-3303.

More Resources:

Comments are closed.